This is a first-in-human, single center, open-label, single arm, dose escalating phase I study. This study will be conducted in 3 parts.~Phase A : Patients will receive single dose of bisthianostat to evaluate the single-dose pharmacokinetics and safety.~Phase B: After single-dose phase, patients will receive multiple dose bisthianostat for 4 weeks on day 1,4,11,14,18,21,25,28 to evaluate the multiple-dose pharmacokinetics and safety~Phase C: Patients will continue on the study if they benefit from the drug and not experience any serious side effects.
This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and efficacy of Bisthianostat in refractory or recurrent multiple myeloma patients.